A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
- 11 July 1996
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 335 (2) , 91-97
- https://doi.org/10.1056/nejm199607113350204
Abstract
The median survival of patients with myeloma after conventional chemotherapy is three years or less. Promising results have been reported with high-dose therapy supported by autologous bone marrow transplantation. We conducted a randomized study comparing conventional chemotherapy and high-dose therapy.Keywords
This publication has 34 references indexed in Scilit:
- Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantationThe International Journal of Cell Cloning, 1996
- A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupEuropean Journal Of Cancer, 1995
- Plasma cell dyscrasiasPublished by American Medical Association (AMA) ,1992
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?European Journal of Cancer and Clinical Oncology, 1989
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969